2016 Medicinal Chemistry Reviews

Volume 51
Manoj C. Desai, Editor-In-Chief

Medicinal Chemistry Reviews is an outstanding 600 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format.

Members can also order a print copy, for the cost of printing, shipping and handling ($40 to US addresses, $85 international) at our secure e-commerce site.

Members: To access your electronic copy:

--Click 'Member Login' in the upper right corner of this page
--On the Member Login page, click the 'Resources' tab.

Nonmembers, libraries and institutions wishing to purchase a copy may visit our secure e-commerce site and purchase at non-member prices.

You may also purchase electronic copies of individual chapters at our secure e-commerce site.

Table of Contents:

Chapter 1	Lessons From Decades of R&D Management
Chapter 2	Recent Developments in Neuropeptide S Receptor (NPSR) Research
Chapter 3	Metabotropic Glutamate Receptors at Thirty: New Insights from Chemical Tools
Chapter 4	Small-Molecule Selective PPAR-gamma Modulators
Chapter 5	Nonpeptide AT2 Receptor Agonists
Chapter 6	Recent Developments in Melanin-Concentrating Hormone Receptor 1 Antagonists
Chapter 7	Targeting Necroptosis for Therapeutic Intervention in Inflammatory Diseases
Chapter 8	Recent Advances in the Discovery and Development of Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists
Chapter 9	Small-Molecule Modulators of Protein Arginine Deaminases (PAD)
Chapter 10	Estrogen Receptor Degraders for the Treatment of ER-positive Breast Cancer
Chapter 11	Small-Molecule Modulators of Keap1-Nrf2
Chapter 12	Small-Molecule Modulators Targeting the Unfolded Protein Response Sensor IRE1-alpha
Chapter 13	Approaches to Eradicate HIV Infection
Chapter 14	Therapeutics for Treatment of Ebola and Other Filovirus Infections
Chapter 15	Polymyxins Targeting the Outer Membrane of Gram-Negative Bacteria
Chapter 16	Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease
Chapter 17	Targeting beta-Amyloid and Tau Protein Oligomers and Aggregates as a Novel Approach to the Treatment of Alzheimer's Disease
Chapter 18	Development of VEGFR Inhibitors as Antiangiogenic Agents
Chapter 19	Recent Developments in Chiral Phosphorothioate Oligonucleotides
Chapter 20	Boron in Medicinal Chemistry
Chapter 21	Protein Degraders: Moving Towards Therapeutically Viable Agents
Chapter 22	Case History: The Discovery of the First Hepatitis C Virus NS5A Replication Complex Inhibitor Daclatasvir (Daklinza™)
Chapter 23	Case History: Vorapaxar (Zontivity®): A First-In-Clas Protease-Activated Receptor-1 (PAR-1) Antagonist Antiplatelet Agent
Chapter 24	New Chemical Entities Entering Phase III Trials in 2015
Chapter 25	To Market, To Market--2015

2016 Medicinal Chemistry Reviews

ACS Division of Medicinal Chemistry